ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer
The addition of nimotuzumab to gemcitabine (Gemzar) increases overall survival in patients with K-Ras wild-type advanced pancreatic…
Browsing: Featured
ASCO 2022: ctDNA may help identify the need for adjuvant therapy in stage II colon cancer
In patients with stage II colon cancer where cancer DNA was not present in the…
ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy
Based on guidance from biomarker screening, patients who are 55 years of age and older…
ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…
New research: 1.4 million Australians will die of cancer in the next 25 years
New research by the Daffodil Centre, at Cancer Council NSW and the University of Sydney,…
Robots at School! Helping Young Cancer Patients Connect
By Dr Jennifer Cohen,(1,2), Ms Thomasin Powell(1), Associate Professor Pandora Patterson(1,3) As lockdowns ease in…
Robots in School!
Today’s episode is all about robots! Yes, the wonderful folks over at Canteen have a…
Cancer groundshot: Access to proven treatments must parallel development of new therapies
Bishal Gyawali, Queen’s University, Ontario Where should investment be made today in order to save…
Scientists find sea corals are source of sought-after “anti-cancer” compound
The bottom of the ocean is full of mysteries but scientists have recently uncovered one…
Patient voices a good predictor of cancer treatment outcomes
A breast cancer patient’s perspective on their physical well-being can provide a better indication of…